RCUS Arcus Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NYSE: RCUS

Price (delayed)

$15.06

Market cap

$1.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4

Enterprise value

$943.32M

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. ...

Highlights
Arcus Biosciences's debt has plunged by 100% YoY
The gross profit has plunged by 72% YoY
RCUS's revenue has shrunk by 72% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.arcusbio.com
Peers: OMGA

Key stats

What are the main financial stats of RCUS
Market
Shares outstanding
74.86M
Market cap
$1.13B
Enterprise value
$943.32M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.16
Price to sales (P/S)
9.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.88
Earnings
Revenue
$119.66M
EBIT
-$288.46M
EBITDA
-$274.03M
Free cash flow
-$306.12M
Per share
EPS
-$4
Free cash flow per share
-$4.1
Book value per share
$6.98
Revenue per share
$1.6
TBVPS
$15.97
Balance sheet
Total assets
$1.19B
Total liabilities
$671M
Debt
$0
Equity
$520M
Working capital
$682M
Liquidity
Debt to equity
0
Current ratio
4.41
Quick ratio
4.26
Net debt/EBITDA
0.67
Margins
EBITDA margin
-229%
Gross margin
100%
Net margin
-245.3%
Operating margin
-270.3%
Efficiency
Return on assets
-23.4%
Return on equity
-50.1%
Return on invested capital
-33.9%
Return on capital employed
-29.1%
Return on sales
-241.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RCUS stock price

How has the Arcus Biosciences stock price performed over time
Intraday
3.01%
1 week
8.58%
1 month
0.74%
1 year
-57.18%
YTD
-27.18%
QTD
-16.1%

Financial performance

How have Arcus Biosciences's revenue and profit performed over time
Revenue
$119.66M
Gross profit
$119.66M
Operating income
-$323.44M
Net income
-$293.46M
Gross margin
100%
Net margin
-245.3%
The gross profit has plunged by 72% YoY
RCUS's revenue has shrunk by 72% YoY
The operating margin has declined by 4% since the previous quarter
Arcus Biosciences's operating income has decreased by 3.2% from the previous quarter

Growth

What is Arcus Biosciences's growth rate over time

Valuation

What is Arcus Biosciences stock price valuation
P/E
N/A
P/B
2.16
P/S
9.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.88
RCUS's equity is down by 26% year-on-year and by 8% since the previous quarter
RCUS's price to book (P/B) is 23% lower than its 5-year quarterly average of 2.8 and 10% lower than its last 4 quarters average of 2.4
RCUS's revenue has shrunk by 72% YoY
RCUS's P/S is 66% below its 5-year quarterly average of 28.0 and 22% below its last 4 quarters average of 12.0

Efficiency

How efficient is Arcus Biosciences business performance
RCUS's ROIC is down by 10% from the previous quarter
The return on equity has declined by 10% since the previous quarter
Arcus Biosciences's return on assets has decreased by 6% QoQ
RCUS's return on sales is down by 2.2% since the previous quarter

Dividends

What is RCUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RCUS.

Financial health

How did Arcus Biosciences financials performed over time
The total assets is 77% greater than the total liabilities
RCUS's quick ratio is down by 30% year-on-year and by 21% since the previous quarter
RCUS's current ratio is down by 29% YoY and by 20% from the previous quarter
Arcus Biosciences's debt is 100% less than its equity
RCUS's debt to equity has dropped by 100% year-on-year
Arcus Biosciences's debt has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.